Research programme: diabetes therapeutics - Arena Pharmaceuticals

Drug Profile

Research programme: diabetes therapeutics - Arena Pharmaceuticals

Alternative Names: GPR119 agonists - Arena Pharmaceuticals; JNJ-28630355

Latest Information Update: 11 Mar 2011

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Pyrimidines; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 10 Mar 2011 Research programme: diabetes therapeutics - Arena Pharmaceuticals is available for licensing. http://www.arenapharm.com
  • 09 Nov 2010 Ortho-McNeil-Janssen Pharmaceuticals announces termination of its collaboration with Arena Pharmaceuticals
  • 19 Dec 2008 Ortho-McNeil advances Arena's GPR119 agonist into phase I development for the treatment of type 2 diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top